Get started
Author

Preethi Janardhanan

Observed name: P Janardhanan
ORCID: 0000-0003-3719-7938
Observed ORCID: 0000-0003-3719-7938
OpenAlex ID: A5064856464
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
2020 · Nikolaos Ioannou, Patrick R. Hagner, et al. · Blood · 50
CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma
2021 · Soraya Carrancio, Lynda Groocock, et al. · Blood · 30
Targeted overexpression of endothelial nitric oxide synthase in endothelial cells improves cerebrovascular reactivity in Ins2 Akita -type-1 diabetic mice
2015 · Saurav B Chandra, Sumathy Mohan, et al. · Journal of Cerebral Blood Flow & Metabolism · 17
Enhancing eNOS activity with simultaneous inhibition of IKKβ restores vascular function in Ins2Akita+/− type-1 diabetic mice
2015 · Manickam Krishnan, Preethi Janardhanan, et al. · Laboratory Investigation · 9
PDF
Anti‐CRLF2 Antibody‐Armored Biodegradable Nanoparticles for Childhood B‐ALL
2013 · Rekha Raghunathan, Swetha Mahesula, et al. · Particle & Particle Systems Characterization · 8
Cc‐99282 Is a Novel Cereblon E3 Ligase Modulator (celmod) Agent With Potent and Broad Antitumor Activity in Preclinical Models of Diffuse Large B‐cell Lymphoma (dlbcl)
2021 · A Lopez‐Girona, L Groocock, et al. · Hematological Oncology · 7
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
2025 · Zhongying Mo, Lynda Groocock, et al. · Blood Cancer Discovery · 5
Abstract 3932: Pathway interaction and mechanistic synergy of CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, with enhancer of zeste homolog 2 inhibitors (EZH2is)
2022 · Soraya Carrancio, Celia Fontanillo, et al. · Cancer Research · 3
Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL)
2022 · Zhongying Mo, Lynda Groocock, et al. · Blood · 2
NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma
2026 · Bo Hu, Jacob T. Edwards, et al. · Blood · 1
PDF
Abstract 3305: Golcadomide (CC-99282) is a novel CELMoD® agent with antiproliferative activity and combinatorial potential in disease models of chronic lymphocytic leukemia
2024 · Antonia Lopez-Girona, Maria Dolores Jimenez-Nunez, et al. · Cancer Research · 1
Supplementary Tables 1-16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
2026 · Zhongying Mo, Lynda Groocock, et al.
Data from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
2026 · Zhongying Mo, Lynda Groocock, et al.
Supplementary Figures S1-S16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
2026 · Zhongying Mo, Lynda Groocock, et al.
Abstract 208: Improved Vasodilatory Function in Ins2Akita Type 1 Diabetic Mice with Daily Intake of Oral L-Arginine in Combination with Salsalate
2014 · Manikcam Krishnan, Preethi Janardhanan, et al. · Arteriosclerosis Thrombosis and Vascular Biology
Abstract 345: Inhibitor Kappa B Kinase Regulates Nitric Oxide Synthase Activity in Vascular Endothelial Cells
2014 · Mohan Natarajan, Manikcam Krishnan, et al. · Arteriosclerosis Thrombosis and Vascular Biology
Investigating the role of ERK2 in peripheral T cell function using a novel transgenic mouse model
2012 · Preethi Janardhanan · The Journal of Immunology
Investigating the Role of ERK2 in Peripheral T cells Function Using a Novel Transgenic Mouse Model (47.13)
2012 · Preethi Janardhanan, Gwendolyn Quintana, et al. · The Journal of Immunology
A micturition switch in the periaqueductal grey matter in rats
2011 · Ella Stone, Preethi Janardhanan, et al.
Works count: 19
Citation count: 133
H-index: 6
I10-index: 3
Year
Topic
Type